Amgen’s Blincyto (blinatumomab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat ...

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

NHS England has announced that it has appointed Sir James Mackey as its new chief executive officer (CEO), following Amanda ...

At Precision Medicine Group (PMG), DEI is a key consideration across the drug development process, especially when it comes to patient engagement in clinical trials. We start with insights and a firm ...